MedTrace Logo

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

NCT00780806 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2011-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.

Conditions

  • Meningitis, Meningococcal

Interventions

BIOLOGICAL

meningococcal B rLP2086 vaccine candidate

vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months

PROCEDURE

Blood draw

Blood draw

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780806 on ClinicalTrials.gov